Prestige Consumer Healthcare Inc. (NYSE: PBH) announced that its senior management team will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The session offers investors an opportunity to engage directly with executive leadership regarding the company’s strategic direction and operational performance in the consumer healthcare sector.

Christine Sacco, Chief Financial Officer and Chief Operating Officer, and Phil Terpolilli, Vice President of Investor Relations, Treasury, and Business Development, are scheduled to appear at the event. The conference takes place on Wednesday, August 12, 2026, beginning at 10:00 a.m. ET. This appearance aligns with standard corporate communication practices for publicly traded companies seeking to maintain transparency with their shareholder base.

Event Details and Access

The fireside chat will be broadcast live to accommodate remote participation. Prestige Consumer Healthcare has made the webcast accessible through its official investor relations portal. Investors can access the stream via the "Investors" section under the "Events and Presentations" tab on www.prestigeconsumerhealthcare.com . A direct link is also provided through the company’s dedicated events page.

For those unable to view the session live, a replay will be available on the company’s website following the conclusion of the event. This ensures that all stakeholders have the opportunity to review the discussion materials regardless of time zone or scheduling conflicts.

Company Overview

Prestige Consumer Healthcare markets, sells, manufactures, and distributes consumer healthcare products to retail outlets throughout the U.S., Canada, Australia, and other international markets. The company manages a diverse portfolio of well-known brands across several therapeutic categories.

Key brands in the portfolio include Breathe Right nasal strips, Monistat and Summer’s Eve women’s health products, BC and Goody’s pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden’s sore throat treatments, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, Gaviscon antacid in Canada, Hydralyte rehydration products, and the Dermal Therapy line of therapeutic skin care products in Australia.

Investors seeking further information may contact Phil Terpolilli at 914-524-6819 or via email at irinquiries@prestigebrands.com .

Prestige Consumer Healthcare, listed on the New York Stock Exchange under the ticker PBH, has upgraded its financial outlook for fiscal year 2027, signaling stronger-than-expected growth in both profitability and top-line revenue. The company raised its adjusted earnings per share (EPS) guidance from a previous range of $4.42-$4.51 to a new band of $4.55-$4.65. This upward revision places the midpoint of the new guidance above the analyst estimate of $4.53, indicating improved operational confidence and margin resilience.

Simultaneously, Prestige Consumer Healthcare increased its full-year sales guidance significantly. The revised sales outlook now stands at $1.290 billion-$1.315 billion, a substantial increase from the earlier projection of $1.100 billion-$1.121 billion. This revised range also exceeds the consensus analyst estimate of $1.179 billion, suggesting that the company anticipates robust demand or successful execution of its commercial strategies in the coming quarters.

Revised Financial Guidance

The updated figures reflect a notable shift in the company’s trajectory for FY2027. By raising both the EPS and sales bands, management is communicating that underlying business performance is tracking ahead of initial expectations. The gap between the new lower-bound sales figure of $1.290 billion and the previous upper bound of $1.121 billion highlights a significant expansion in revenue potential.

What the Numbers Show

The divergence between the revised sales guidance and the analyst estimate is particularly material. While the EPS revision is modestly above the street estimate, the sales uplift is more pronounced, adding approximately $111 million to $136 million to the expected annual revenue compared to the prior ceiling. This suggests that the earnings improvement may be driven not just by cost efficiencies but by genuine volume or price realization gains. The ability to raise the floor of the sales guidance well above the previous ceiling indicates a strong momentum shift in the company’s core markets.